Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
Taiwan · Delayed Price · Currency is TWD 29.20
-0.05 (-0.17%)
At close: Mar 27, 2026
TPEX:4111 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 164.28 | 110.63 | 68.67 | 154.01 | 80.75 |
Depreciation & Amortization | 74.25 | 66.3 | 61.96 | 72.88 | 79.08 |
Loss (Gain) From Sale of Assets | 0.82 | 2.38 | 0.13 | 4.96 | -0.12 |
Asset Writedown & Restructuring Costs | - | - | - | - | -6.8 |
Provision & Write-off of Bad Debts | 0.01 | 0.01 | - | -0 | 0 |
Other Operating Activities | 58.16 | 26.08 | -17.01 | -17.16 | 32.71 |
Change in Accounts Receivable | -23.99 | -28.25 | -26.6 | 9.17 | -36.81 |
Change in Inventory | -6.53 | -7.68 | 9.86 | -8.83 | -4.86 |
Change in Accounts Payable | 117.58 | 22.41 | -16.49 | 17.5 | 4.76 |
Change in Unearned Revenue | -0.13 | -1.03 | -3.6 | -3.02 | -4.21 |
Change in Other Net Operating Assets | -109.84 | 22.34 | -2.4 | 10.63 | 21.78 |
Operating Cash Flow | 274.61 | 213.2 | 74.52 | 214.86 | 139.33 |
Operating Cash Flow Growth | 28.80% | 186.10% | -65.32% | 54.21% | -2.93% |
Capital Expenditures | -93.86 | -84.19 | -101.5 | -105.33 | -264.86 |
Sale of Property, Plant & Equipment | 0.59 | 0.31 | 0.41 | 0.07 | 0.12 |
Divestitures | - | - | - | 168.97 | - |
Sale (Purchase) of Intangibles | -0.68 | -1.03 | -0.5 | -0.52 | -0.65 |
Sale (Purchase) of Real Estate | -1.86 | - | - | - | - |
Investment in Securities | - | - | - | - | 1.37 |
Other Investing Activities | -1.36 | -1.4 | 24.97 | 0.06 | -25 |
Investing Cash Flow | -97.17 | -86.31 | -76.61 | 63.24 | -289.02 |
Short-Term Debt Issued | - | - | - | - | 130 |
Total Debt Issued | - | - | - | - | 130 |
Short-Term Debt Repaid | - | -110 | - | -10 | - |
Long-Term Debt Repaid | -12.76 | -4.77 | -5.65 | -7.03 | -6.46 |
Total Debt Repaid | -12.76 | -114.77 | -5.65 | -17.03 | -6.46 |
Net Debt Issued (Repaid) | -12.76 | -114.77 | -5.65 | -17.03 | 123.54 |
Common Dividends Paid | -56.98 | -56.98 | -68.38 | -56.98 | -56.98 |
Other Financing Activities | 0.01 | 0 | 0.92 | -0.87 | 0.12 |
Financing Cash Flow | -69.73 | -171.75 | -73.11 | -74.88 | 66.68 |
Foreign Exchange Rate Adjustments | - | - | - | 0.77 | -0.52 |
Net Cash Flow | 107.72 | -44.86 | -75.21 | 203.98 | -83.53 |
Free Cash Flow | 180.75 | 129.01 | -26.98 | 109.53 | -125.53 |
Free Cash Flow Growth | 40.11% | - | - | - | - |
Free Cash Flow Margin | 13.13% | 11.07% | -2.54% | 9.58% | -12.28% |
Free Cash Flow Per Share | 2.99 | 2.15 | -0.45 | 1.82 | -2.09 |
Cash Interest Paid | 0.52 | 1.85 | 1.44 | 1.5 | 1.03 |
Cash Income Tax Paid | -15.55 | 1.41 | 34.74 | 25.39 | 18.44 |
Levered Free Cash Flow | 161.43 | 40.28 | -50.71 | 105.66 | -140.99 |
Unlevered Free Cash Flow | 161.76 | 41.37 | -49.8 | 106.61 | -140.31 |
Change in Working Capital | -22.92 | 7.79 | -39.24 | 25.45 | -19.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.